Every Form 4 that Crinetics Pharmaceuticals (CRNX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CRNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRNX filings page.
Crinetics Pharmaceuticals, Inc. (CRNX) completed a merger in which it became a wholly owned subsidiary of Vertex Pharmaceuticals. At the September 1, 2026 effective time, each share of Crinetics common stock was canceled and converted into the right to receive $85.00 in cash per share.
Director Wendell Wierenga reported only merger-related equity cancellations and cash-outs. 116,146 shares of common stock were canceled for the $85.00 cash consideration, and 5,925 restricted stock units became fully vested and were converted into cash at the same $85.00 per-share amount, less tax withholding.
Multiple tranches of stock options were also canceled. Each vested option with an exercise price below $85.00 was converted into the right to receive cash equal to the difference between $85.00 and its exercise price (for example, options with a $23.24 exercise price yielded $61.76 per option). Options with exercise prices at or above $85.00 were canceled for no consideration. These are issuer-related merger settlements, not open‑market trades.
Crinetics Pharmaceuticals, Inc. (CRNX) director Vivaldi Coelho Rogerio reported issuer-related dispositions on September 1, 2026 in connection with Crinetics’ merger into a wholly owned subsidiary of Vertex Pharmaceuticals. At the merger’s effective time, each Crinetics common share was canceled and converted into the right to receive $85.00 in cash per share, subject to tax withholding. The filing shows cancellation of common stock, restricted stock units, and stock options, which were converted into cash equal to the merger consideration (for shares and RSUs) or, for in-the-money options, the difference between the $85.00 merger consideration and the option exercise price, with underwater options canceled for no consideration.
Crinetics Pharmaceuticals, Inc. (CRNX) reports that director Stephanie Okey’s equity awards were canceled in connection with the merger under which Vertex Pharmaceuticals acquired Crinetics. Effective September 1, 2026, each share of Crinetics common stock was converted into the right to receive $85.00 in cash, and Ms. Okey’s outstanding restricted stock units and stock options were canceled and converted into cash rights based on this merger consideration, less applicable exercise prices and tax withholdings. The Form 4 reflects these cancellations as dispositions to the issuer rather than open-market trades.
Crinetics Pharmaceuticals, Inc. (CRNX) director Weston Nichols reported the treatment of his equity awards in connection with the merger under which Crinetics became a wholly owned subsidiary of Vertex Pharmaceuticals. At the September 1, 2026 effective time, each share of Crinetics common stock was canceled and converted into the right to receive $85.00 per share in cash. Nichols’ restricted stock units became fully vested immediately before closing, then were canceled and converted into cash equal to the $85.00 merger consideration per unit, less applicable tax withholding. His outstanding stock options were also canceled: options with exercise prices below $85.00 were converted into cash equal to the difference between $85.00 and the exercise price per option share (as reflected in Column 8 of the option rows), while options with exercise prices at or above $85.00 were canceled for no consideration. All transactions are coded as dispositions to the issuer reflecting this merger-driven cash-out rather than open-market trading.
Crinetics Pharmaceuticals, Inc. (CRNX) completed a merger with Vertex Pharmaceuticals effective September 1, 2026, in which each Crinetics common share was canceled and converted into the right to receive $85.00 in cash per share. Director Matthew K. Fust reported automatic, merger-related dispositions of 22,836 common shares and 5,925 RSU-equivalent shares, plus five stock option grants covering 52,172 shares. In-the-money options were canceled and converted into cash equal to $85.00 minus the applicable exercise price per option share, while any options with exercise prices at or above $85.00 were canceled for no consideration. These were structured cancellations to issuer in the merger, not open-market trades.
Crinetics Pharmaceuticals, Inc. (CRNX) director Caren Deardorf reported transactions triggered by the closing of the merger in which Crinetics became a wholly owned subsidiary of Vertex Pharmaceuticals. At the September 1, 2026 effective time, each share of Crinetics common stock was canceled and converted into the right to receive $85.00 per share in cash, subject to tax withholding. Deardorf reported 16,300 shares of common stock and 5,925 shares underlying restricted stock units being canceled and converted into cash rights at this merger consideration. In addition, multiple stock option grants were canceled; options with exercise prices below the $85.00 merger consideration were converted into cash equal to the difference between $85.00 and the option’s exercise price per share, while options with exercise prices at or above $85.00 were canceled for no consideration.
Crinetics Pharmaceuticals, Inc. (CRNX) completed a merger under which it became a wholly owned subsidiary of Vertex Pharmaceuticals, with each Crinetics common share converted into the right to receive $85.00 in cash at the September 1, 2026 effective time. Director Camille L. Bedrosian reported disposition to the issuer of common stock and equity awards in connection with this closing. The filing shows cancellation-for-cash of multiple tranches of stock options, each covering specified numbers of shares at exercise prices below $85.00, and the cash-out of restricted stock units that first vested in full and then converted into cash at the same $85.00 per-share Merger Consideration, less applicable tax withholding.
Crinetics Pharmaceuticals, Inc. (CRNX) disclosed that Chief Commercial Officer Isabel Kalofonos reported merger-related dispositions effective September 1, 2026. In connection with the merger of Crinetics into a wholly owned subsidiary of Vertex Pharmaceuticals, each share of Crinetics common stock was canceled and converted into the right to receive $85.00 per share in cash, subject to tax withholding. The filing reports cancellation of common shares, restricted stock units and stock options, which were converted into cash rights based on the Merger Consideration or, for certain out-of-the-money options, canceled for no consideration.
Crinetics Pharmaceuticals, Inc. (CRNX) reports that Chief Scientific Officer Stephen F. Betz had his equity interests canceled and settled in cash in connection with the merger under which Crinetics became a wholly owned subsidiary of Vertex Pharmaceuticals Incorporated. On September 1, 2026, all common shares and restricted stock units were converted into the right to receive $85.00 per share in cash, subject to tax withholding. On the same date, multiple outstanding stock options were canceled: options with exercise prices below $85.00 were converted into cash equal to the $85.00 merger consideration minus the applicable exercise price per option share, while options with exercise prices at or above $85.00 were canceled for no consideration. A total of 13 disposition-to-issuer transactions were reported, reflecting this merger-driven cancellation and cash-out of Betz’s equity awards.
Crinetics Pharmaceuticals, Inc. (CRNX) reported that Chief Financial & Infra. Officer Tobin Schilke’s equity awards were cashed out in connection with the merger under which Crinetics became a wholly owned subsidiary of Vertex Pharmaceuticals, effective September 1, 2026. Each Crinetics common share was canceled and converted into the right to receive $85.00 per share in cash.
The filing shows disposition to the issuer of 7,956 common shares at $85.00 per share and the cancellation of 71,471 restricted stock units, each converted into cash equal to the $85.00 merger price, less tax withholding. It also reports the cancellation of 80,000 and 50,000 stock options, each converted into cash equal to the $85.00 merger price minus the respective exercise prices, with unvested options and RSUs vesting immediately before the merger.
Crinetics Pharmaceuticals, Inc. (CRNX) reports that, effective September 1, 2026, it became a wholly owned subsidiary of Vertex Pharmaceuticals under an Agreement and Plan of Merger. At the effective time, each outstanding share of Crinetics common stock was canceled and converted into the right to receive $85.00 in cash per share, subject to tax withholding. The filing shows cancellation of both directly and indirectly held common shares (including spouse, family trusts, and a charitable trust) and cancellation of various employee stock options and restricted stock units, which were converted into cash equal to the merger consideration (or, for options, the cash difference between the $85.00 merger price and the option exercise price).
Crinetics Pharmaceuticals, Inc. (CRNX) reported that Chief Financial & Infra. Ofcr. Tobin Schilke received a grant of 471 restricted stock units (RSUs) of common stock. These RSUs vest 25% annually beginning on September 1, 2027. Following this award, Schilke directly holds 79,427 shares of common stock, including 835 shares acquired through the company’s Employee Stock Purchase Plan.
Crinetics Pharmaceuticals, Inc. reported that President & CEO Richard Scott Struthers exercised stock options on August 7, 2026 to acquire a total of 19,928 shares of common stock through four option exercises. The options had exercise prices of $25.19, $22.61, $20.02, and $15.29 per share. Indirect holdings include common stock held by multiple family trusts and a charitable trust, with examples such as 136,805 shares held by Family Trust 1 and 80,000 shares held by a Charitable Trust. No sales of common stock are reported in this filing.
Crinetics Pharmaceuticals director Vivaldi Coelho Rogerio sold 3,000 shares of Common Stock in an open-market transaction at $40.00 per share. The trade occurred on July 2, 2026 and was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Following this sale, he directly holds 19,225 Crinetics shares.
Crinetics Pharmaceuticals director Caren Deardorf received new equity awards in the form of restricted stock units and stock options. She was granted 5,925 restricted stock units, representing the right to receive the same number of common shares, which vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to her continued board service.
She was also granted stock options covering 9,730 shares of common stock at an exercise price of $35.87 per share, expiring on June 18, 2036, with the same vesting schedule. Following these awards, she directly holds 22,225 shares of common stock, in addition to the new option position.
Crinetics Pharmaceuticals director Matthew K. Fust received new equity awards as board compensation. He was granted 5,925 restricted stock units representing common shares at no purchase price, increasing his direct holdings to 28,761 common shares after the award.
Fust was also granted stock options for 9,730 shares of common stock at an exercise price of $35.87 per share, expiring on June 18, 2036. Both the restricted stock units and options vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual shareholder meeting, subject to his continued board service.
Crinetics Pharmaceuticals director Nichols Weston received new equity awards. The filing shows a grant of 5,925 shares of common stock in the form of restricted stock units, bringing his direct common share holdings to 22,225. He was also granted a stock option over 9,730 shares of common stock at an exercise price of $35.87 per share, expiring on June 18, 2036. Both the restricted stock units and the option vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual meeting of stockholders, subject to his continued service on the board.
Crinetics Pharmaceuticals director Vivaldi Coelho Rogerio received equity compensation on June 18, 2026. He was granted 5,925 shares of Common Stock in the form of restricted stock units that vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued board service. He also received options for 9,730 shares of Common Stock at an exercise price of $35.87 per share, vesting on the same schedule and expiring on June 18, 2036. Following these grants, he directly holds 22,225 Common Shares and 9,730 stock options.
Crinetics Pharmaceuticals director Camille L. Bedrosian reported receiving new equity awards. She was granted 5,925 restricted stock units representing rights to receive Common Stock, vesting 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual stockholder meeting, subject to continued board service.
She also received stock options for 9,730 shares of Common Stock at an exercise price of $35.87 per share, expiring on June 18, 2036, with the same vesting schedule. After these awards, she directly holds 22,225 shares of Common Stock and 9,730 options.
Crinetics Pharmaceuticals director Wendell Wierenga received new equity awards in the form of stock and options. He was granted 5,925 shares of Common Stock as restricted stock units at no cost, bringing his direct holdings to 122,071 shares after the grant.
He also received a stock option covering 9,730 shares of Common Stock with an exercise price of $35.87 per share and an expiration date in 2036. Both the restricted stock units and the option vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual stockholder meeting, subject to his continued service on the board.
Crinetics Pharmaceuticals director Stephanie Okey received new equity awards as board compensation. She was granted 5,925 restricted stock units representing future common shares and a stock option for 9,730 shares at an exercise price of $35.87 per share. The restricted stock units and option vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on her continued board service. Following the grant, she holds 12,325 shares of common stock directly.
Crinetics Pharmaceuticals director Stephanie Okey reported selling a total of 6,900 shares of Common Stock in open-market transactions. The sales on June 17, 2026 were executed under a pre-arranged Rule 10b5-1 trading plan, at volume-weighted average prices of $35.62 and $36.22 per share.
Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported a series of estate and charitable planning moves involving gifts of 1,937,600 shares of common stock on May 29, 2026. The transactions are coded as bona fide gifts, with reported prices of $0.0000 per share, indicating no sale proceeds.
The gifts include transfers among multiple family trusts, a charitable remainder trust, and his spouse, with the filing noting that he disclaims beneficial ownership of certain trust-held shares except for his pecuniary interest. Following these transactions, he continues to hold significant positions, including 626,978 shares directly and 439,005 shares indirectly through Family Trust 1.
Crinetics Pharmaceuticals Chief Dev. & Operating Officer Jeff E. Knight reported an exercise-and-sale transaction in company stock. On April 8, 2026, he exercised stock options to acquire a total of 78,434 shares of Common Stock at exercise prices of $23.98, $20.02, and $19.64 per share.
On the same date, Knight sold 85,163 shares of Common Stock in open market transactions at a volume weighted average price of $40.10 per share, with individual sale prices ranging from $40.00 to $40.34. The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 105,289 shares of Crinetics common stock.
Crinetics Pharmaceuticals Chief Operating Officer Jeff E. Knight sold 9,911 shares of common stock in open-market transactions. The sales on March 16, 2026 were executed at volume-weighted average prices of $37.11 and $37.77 per share.
According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of previously granted restricted stock units and were carried out by a broker under a Rule 10b5-1 trading plan. After the transactions, Knight directly holds 112,018 shares of Crinetics common stock.
Crinetics Pharmaceuticals Chief Scientific Officer Stephen F. Betz reported selling a total of 10,612 shares of common stock on March 16, 2026 in open-market transactions. One block of 6,371 shares was sold at a volume-weighted average price of $37.11 per share, and another 4,241 shares at $37.77 per share.
According to the footnotes, these sales were made to cover his tax withholding obligations upon the vesting of previously granted restricted stock units and were executed by a broker under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Betz directly holds 137,101 shares of Crinetics common stock.
Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported tax-related share sales. On March 16, 2026, he sold a total of 21,981 shares of common stock in open-market transactions, including 13,196 shares at a volume-weighted average price of $37.11 and 8,785 shares at $37.77.
According to the disclosure, these shares were sold by a broker to cover the CEO's tax withholding obligations upon the vesting of restricted stock units granted on February 28, 2022, March 1, 2023, and March 4, 2024, under a Rule 10b5-1 trading plan. After the sales, he directly holds 404,778 shares of common stock and has additional indirect holdings through several family trusts and his spouse.
Crinetics Pharmaceuticals director Rogerio Vivaldi Coelho sold 5,000 shares of Common Stock in open-market transactions. The sales occurred on March 12, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, meaning the trades were scheduled in advance.
The transactions comprised 4,477 shares at a volume-weighted average price of $36.08 and 523 shares at a volume-weighted average price of $36.77, within disclosed intraday price ranges. Following these sales, he directly held 16,300 shares of Crinetics Pharmaceuticals common stock.
Crinetics Pharmaceuticals director Stephanie Okey reported an open-market sale of 3,000 shares of common stock at $39.67 per share on March 3, 2026. The trade was executed automatically under a Rule 10b5-1 trading plan adopted on November 19, 2025, and she now holds 13,300 shares.
Crinetics Pharmaceuticals Chief Financial Officer Tobin Schilke reported an automatic sale of common stock tied to tax withholding. On the transaction date, 6,713 shares of common stock were sold in open-market transactions to cover his tax withholding obligation upon the vesting of restricted stock units granted on March 10, 2025.
The shares were sold pursuant to a pre-arranged Rule 10b5-1 trading plan, with a volume-weighted average price of $39.67 per share and a sale price range of $39.67 to $39.74 per share. After this tax-related sale, he directly held 78,121 shares of Crinetics common stock.
Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported equity awards and updated his holdings. He received a stock option for 228,000 shares of Common Stock at an exercise price of $0.00, vesting in forty-eight equal monthly installments starting on February 23, 2026. He also received 62,000 restricted stock units, which vest 25% annually beginning on March 1, 2027. The filing also reflects indirect ownership of Common Stock through four family trusts and a spouse, with separate reported balances for each entity.
Crinetics Pharmaceuticals Chief Financial Officer Tobin Schilke reported new equity awards. On February 23, 2026, Schilke was granted stock options for 50,000 shares of Crinetics common stock at an exercise price of $0.0000 per share, held as direct ownership.
He also received 32,000 shares of common stock as a grant described in the footnotes as restricted stock units. These units vest 25% annually beginning on March 1, 2027. Following the grant, Schilke directly owned 84,834 shares of common stock, which includes 834 shares acquired under the company’s Employee Stock Purchase Plan.
The stock options vest and become exercisable in 48 equal monthly installments starting from the vesting commencement date of February 23, 2026, spreading the vesting over four years.
Crinetics Pharmaceuticals, Inc. Chief Operating Officer Jeff E. Knight reported receiving new equity awards. He was granted stock options for 55,000 shares of common stock at an exercise price of $0.0000 per share and 34,000 restricted stock units representing common shares.
The RSUs vest with 25% of the award vesting annually beginning on March 1, 2027, providing staggered delivery of common shares over four years. The stock options vest in forty-eight equal monthly installments starting on February 23, 2026, creating a four-year monthly vesting schedule tied to continued service.
After these awards, Knight directly owned 121,929 shares of common stock, which includes 438 shares acquired under the company’s employee stock purchase plan, as well as 55,000 stock options from this grant.
Crinetics Pharmaceuticals, Inc. reported that Chief Scientific Officer Stephen F. Betz
He received a stock option covering 47,000 shares of common stock, vesting in forty-eight equal monthly installments starting from a vesting commencement date of February 23, 2026. He also received 30,000 restricted stock units, each representing a right to receive one share of common stock, with 25% vesting annually beginning on March 1, 2027. Both awards were reported at a price per share of $0.00, reflecting grants rather than open‑market purchases.
Crinetics Pharmaceuticals, Inc. reported that Chief Commercial Officer Isabel Kalofonos received new equity awards on February 23, 2026. She was granted stock options for 55,000 shares of common stock at an exercise price of $0.00 and 34,000 shares of common stock as restricted stock units.
The restricted stock units represent the right to receive common shares, with 25% vesting annually beginning on March 1, 2027. The stock option vests in forty-eight equal monthly installments starting from February 23, 2026, aligning the CCO’s compensation with long-term company performance through time-based vesting.
Crinetics Pharmaceuticals’ Chief Commercial Officer, Isabel Kalofonos, reported routine insider transactions. On January 5, 2026, she exercised a stock option for 2,500 shares of common stock at an exercise price of $40.59 per share, converting derivative securities into common stock. That same day, she sold 2,500 shares of common stock in an open‑market transaction at $55.00 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on June 7, 2025.
Following these transactions, Kalofonos directly beneficially owned 834 shares of common stock, which include shares acquired under the company’s employee stock purchase plan, and held 97,500 stock options after the reported option exercise.
Crinetics Pharmaceuticals (CRNX) reported an insider transaction by its Chief Medical and Development Officer. On November 3, 2025, the officer exercised 5,000 stock options at an exercise price of $16.89 per share and, on the same date, sold 4,900 shares at a volume‑weighted average price of $42.65 (price range $42.14–$43.09) and 100 shares at $43.27.
The sales were effected pursuant to a Rule 10b5‑1 trading plan adopted on May 21, 2025. Following the transactions, the officer directly beneficially owned 66,270 shares of common stock. Derivative securities beneficially owned following the transactions were 74,042 stock options. The option grant vests 25% on September 30, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued employment.
Crinetics Pharmaceuticals (CRNX) reporting person Dana Pizzuti executed option exercises and open-market sales on 10/01/2025. The Form 4 shows a stock option exercise for 5,000 shares at an exercise price of $16.89, creating 5,000 underlying shares. The same day, 5,000 shares were sold in open-market transactions under a Rule 10b5-1 trading plan at a volume-weighted average price of $41.81 (range $41.34–$42.16). Following the reported transactions, the reporting person directly owned 66,270 shares. The filer corrected a prior Form 4 that had misstated post-transaction ownership as 96,270 shares; the correction clarifies the true direct ownership.
Crinetics Pharmaceuticals insider sale by President & CEO Richard S. Struthers. The filing reports that on 09/26/2025 Mr. Struthers sold 4,000 shares of common stock in open-market transactions at $45.00 per share under a Rule 10b5-1 trading plan adopted August 30, 2024. The Form 4 lists his post-transaction beneficial holdings across direct and indirect holdings, including 320,017 shares held directly and multiple indirect holdings via family trusts and spouse (for example, 661,205 shares by Family Trust 1 and 106,000 shares indirect by Family Trust 2). The sale was effected automatically under the trading plan and was signed by an attorney-in-fact on 09/30/2025.
Crinetics Pharmaceuticals director Matthew K. Fust reported transactions on 09/26/2025. He exercised 10,000 stock options with a $1.91 exercise price and acquired 10,000 shares, and sold 16,000 shares in open-market transactions at $44.75 per share executed under a Rule 10b5-1 trading plan. After these transactions he beneficially owned 22,836 shares of common stock and held 10,000 stock options (with 2,092 derivative securities reported as beneficially owned following the transactions). The 10,000 options became exercisable per the stated vesting schedule; 1/3 vested on 02/16/2019 with monthly vesting thereafter.